Pathophysiology of dilated cardiomyopathy: from mechanisms to precision medicine
Top Cited Papers
- 11 October 2024
- journal article
- review article
- Published by Springer Nature in Nature Reviews Cardiology
- Vol. 22 (3) , 183-198
Abstract
Dilated cardiomyopathy (DCM) is a complex disease with multiple causes and various pathogenic mechanisms. Despite improvements in the prognosis of patients with DCM in the past decade, this condition remains a leading cause of heart failure and premature death. Conventional treatment for DCM is based on the foundational therapies for heart failure with reduced ejection fraction. However, increasingly, attention is being directed towards individualized treatments and precision medicine. The ability to confirm genetic causality is gradually being complemented by an increased understanding of genotype–phenotype correlations. Non-genetic factors also influence the onset of DCM, and growing evidence links genetic background with concomitant non-genetic triggers or precipitating factors, increasing the extreme complexity of the pathophysiology of DCM. This Review covers the spectrum of pathophysiological mechanisms in DCM, from monogenic causes to the coexistence of genetic abnormalities and triggering environmental factors (the ‘two-hit’ hypothesis). The roles of common genetic variants in the general population and of gene modifiers in disease onset and progression are also discussed. Finally, areas for future research are highlighted, particularly novel therapies, such as small molecules, RNA and gene therapy, and measures for the prevention of arrhythmic death.Keywords
This publication has 195 references indexed in Scilit:
- Assessment of the Diagnostic Yield of Combined Cardiomyopathy and Arrhythmia Genetic TestingJAMA Cardiology, 2022
- Clinical Characterization and Natural History of Chemotherapy-Induced Dilated CardiomyopathyESC Heart Failure, 2022
- Association of Titin Variations With Late-Onset Dilated CardiomyopathyJAMA Cardiology, 2022
- Standardizing the role of endomyocardial biopsy in current clinical practice worldwideEuropean Journal of Heart Failure, 2021
- Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsyEuropean Journal of Heart Failure, 2021
- Viral presence‐guided immunomodulation in lymphocytic myocarditis: an updateEuropean Journal of Heart Failure, 2020
- Association of Titin-Truncating Genetic Variants With Life-threatening Cardiac Arrhythmias in Patients With Dilated Cardiomyopathy and Implanted DefibrillatorsJAMA Network Open, 2019
- Sex- and Age-Based Differences in the Natural History and Outcome of Dilated CardiomyopathyEuropean Journal of Heart Failure, 2018
- Restrictive Cardiomyopathy: An Unusual Phenotype of a Lamin A VariantESC Heart Failure, 2018
- The Innate Immune System in Chronic Cardiomyopathy: A European Society of Cardiology (Esc) Scientific Statement from the Working Group on Myocardial Function of the ESCEuropean Journal of Heart Failure, 2018